Status:
COMPLETED
A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer
Lead Sponsor:
Guangdong Provincial People's Hospital
Collaborating Sponsors:
The People's Hospital of Gaozhou
The General Hospital of Southern Theater Command
Conditions:
Esophageal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The role of preoperative chemotherapy as standard therapy is well-established for advanced esophageal cancer. Immunotherapeutic agents such as Immune checkpoint inhibitors has been shown to improve ob...
Eligibility Criteria
Inclusion
- Pathologically diagnosed as esophageal squamous cell carcinoma
- KPS≥80
- Adequate organ function
- No distant metastasis
- The diseases could be resected or potentially resectable after immunochemotherapy assessed by a thoracic oncologist
Exclusion
- incomplete medical record which affects statistical analysis
- have participated in previous interventional clinical trials
- other situations evaluated by investigators not meet the enrollment
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT04822103
Start Date
January 1 2021
End Date
October 31 2021
Last Update
March 18 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
2
Shantou Central Hospital
Shantou, Guangdong, China, 515031